Kalytera Therapeutics


About

Many approved first-generation cannabinoid medicines are characterized by poor specificity and unwanted side effects, potentially limiting their utility in mass market indications. By making systematic, incremental modifications to cannabinoid molecules, and molecules which regulate the endogenous cannabinoid signaling system, Kalytera intends to eliminate psychoactive properties, reduce or eliminate other unwanted side effects, and advance cannabinoid and cannabinoid-modulating medicines that target specific receptors, allowing for improved drug specificity in each proposed indication. Kalytera Therapeutics is developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines that we believe will address large unmet market needs. Kalytera seeks to commercialize its proprietary synthetic cannabinoid therapies across a range of disease states, with an initial focus on osteoporosis and bone healing. By making systematic, incremental modifications to cannabinoid molecules, and molecules which regulate the endogenous cannabinoid signaling system, Kalytera intends to eliminate psychoactive properties, reduce or eliminate other unwanted side effects, and advance cannabinoid and cannabinoid-modulating medicines that target specific receptors, allowing for improved drug specificity in each proposed indication. OSTEOPOROSIS AND BONE HEALING: Osteoporosis is a chronic condition characterized by a weakening of the bone and an increased risk of fracture. Osteoporosis, the most common bone disease, typically does not manifest until late in life, when bone loss begins due to bone breakdown and decreased levels of bone formation. Loss of bone mass leads to the development of structural abnormalities that make the skeleton more fragile. According to the National Osteoporosis Foundation (“NOF”), osteoporosis affects approximately 10.2 million adults in the U.S. alone. The NOF estimates that an additional 43.4 million U.S. adults may have low bone mass. Globally, one in five men and one in three women aged 50+ will experience osteoporotic fractures. Bone Remodeling: Bone remodeling is a life long process that regulates the gain and loss of bone in adults; osteoporosis occurs when bone resorption by osteoclasts outpaces bone formation by osteoblasts, leading to net bone loss. KAL671 and KAL436 may limit bone loss by modifying the process of bone remodeling. CANNABINOIDS: In recent years, the mainstream medical establishment has regained interest in cannabis for therapeutic applications. This attention has surfaced as researchers began to look more deeply into the substance’s low toxicity and high effectiveness for a variety of ailments. Cannabinoid receptors were first discovered, characterized and cloned in 1990. Over the course of the next few years, these receptors were classified into two subtypes, CB1, which is found in the nervous system and in various organs and tissues throughout the body, and CB2, which is found in the immune system. Shortly after the discovery of cannabinoid receptors came the discovery of the endogenous cannabinoid system – the system that binds cannabinoid receptors with plant based cannabinoids as well as endogenous ligands that exist naturally in the body, referred to as endocannabinoids. Since the discovery of this system, modern scientists have come to believe the cannabinoid system is intimately involved in human physiology, including elements as diverse as the movement control, reproduction, memory, appetite, bone tissue formation, among other functions.

Marijuana Nation - Dr. Raphael Mechoulam

Contact

Kalytera Therapeutics, Inc.
500 S. Sepulveda Blvd., Suite 212
Manhattan Beach, California 90266
United States

Get Directions

Please Login to Claim this listing

Features

  • Next-Generation Cannabinoid Medicines

Be the first to review this item!


Contact

(888) 861-2008


Bookmarking
Bookmark this

Advertisement